NEW YORK — As Americans delay elective surgeries and avoid doctors and hospitals during the coronavirus pandemic, healthcare spending declines have more than offset the added costs of COVID-19 care, insurance executives and experts say, boosting U.S. health insurer profits.
The first study on vitamin D and COVID-19 was released as a preprint on April 23, and a second study was released as a preprint on April 26. Here’s what we can learn from the second study. The first study, which I reported on a few days ago, focused on disease severity, while the second one, which I’m reporting on here, focused on mortality.
The Results
The electronic health records of 780 laboratory-confirmed COVID-19 cases from the government hospitals of Indonesia between March 2 and April 24 was searched for data on vitamin D status prior to admission, age, sex, preexisting conditions, and mortality. Vitamin D status was classified as normal (≥30 ng/mL), insufficient (21−29 ng/mL), or deficient (≤20 ng/mL).
We are going over the latest news, as well as any breakthrough findings on the virus. In today’s updates, we’ll discuss Remdesivir, elevated risk of severe infection in men, COVID toes, UK vaccine trial as well as answer your questions from the comments below.
Numbers update
:04 Remdesivir
:10 Gender differences with COVID-19
:14 Covid Toes
:16 Rare inflammatory syndrome in children.
:18 UK Vaccine trial
:19 Pete the Cat
:20 How Are people carriers without symptoms?
:25 Could COVID-19 vaccine lead to common cold vaccine?
:27 How to clean groceries after shopping?
:29 Do postmenopausal women suffer infections as bad as men?
:32 How are people in the hospital being treated for COVID-19?
:34 How successful is plasma therapy?
:36 How is COVID-19 data being collected?
:39 Can you get reinfected after recovering from the virus?
:42 How long does immunity last (if immune at all)?
:45 Can the virus enter the body thru the eyes/ears.
MilliporeSigma and The Jenner Institute report that the Institute has begun preparations for the large-scale production of its COVID-19 vaccine candidate, ChAdOx1 nCoV-19. With patients enrolled for clinical trials for this vaccine, rapid development of the large-scale manufacturing process is a critical step in quickly and safely delivering it from the lab to patients, according to Udit Batra, CEO, MilliporeSigma.
“We have brought the future of vaccine manufacturing to the present,” said Batra. “This is an important step in treating COVID-19 and other diseases that impact global public health. This work marks a milestone in the vaccine manufacturing development journey, as clinical testing continues to advance.”
Tapping into MilliporeSigma’s previous work provided a head start for plans to scale up the manufacture of Jenner’s COVID-19 vaccine candidate, added Batra. Developing the manufacturing process itself would normally take at least six months to a year, but in just two months’ time, MilliporeSigma supported the Jenner team and their collaborators to evaluate the existing manufacturing platform for use with the new vaccine candidate, and improved critical process steps, he continued.
The study of both fermented and non-fermented soy products was based on the results of research carried out on approximately 90,000 men and women between the ages of 45 and 74 over a period of 15 years. The team calculated intake quantities for all soy products and fermented products only through a dietary survey and examined the relationship with mortality in five similarly sized groups.
Findings from a scientific study help support the long-held belief that fermented soy products like nattō are good for one’s health.
This is very surreal. A study was done to assess the safety of common drugs, and COVID, and whether taking them leads to severe symptoms. There has been concern as these drugs increase ACE2 receptors coronavirus binds to. So someone had the bright idea of going through over 12,000 digital patients records to come up with the conclusion the drugs are safe to take and they do not cause worse symptoms. No animal studies, no clinical trials, and this was actually published.
“For the study, the researchers identified patients in the NYU Langone Health electronic health record with COVID-19 test results. For each identified patient with COVID-19 test results, the team discretely extracted medical history needed for the analysis, which compared treated and untreated patients.”
First you do a mouse study at least to review how coronavirus behaves in mice who are given the drugs, and compare it to mice not given the drugs. If science has been reduced to just going over records and coming to a conclusion, with no experimentation I have officially lost my mind.
The Max Delbrück Center for Molecular Medicine is devoted to biomedical research with the aim of understanding the molecular basis of health and disease and translating findings as quickly as possible into clinical applications. Better prevention, diagnosis and treatment of diseases are the ultimate goals.
Cytokine storms may affect the severity of COVID-19 cases by lowering T cell counts, according to a new study published in Frontiers in Immunology. Researchers studying coronavirus cases in China found that sick patients had a significantly low number of T cells, a type of white blood cell that plays a crucial role in immune response, and that T cell counts were negatively correlated with case severity.
Interestingly, they also found a high concentration of cytokines, a protein that normally helps fight off infection. Too many cytokines can trigger an excessive inflammatory response known as a cytokine storm, which causes the proteins to attack healthy cells. The study suggests that coronavirus does not attack T cells directly, but rather triggers the cytokine release, which then drives the depletion and exhaustion of T cells.
The findings offer clues on how to target treatment for COVID-19, which has become a worldwide pandemic and a widespread threat to human health in the past few months. “We should pay more attention to T cell counts and their function, rather than respiratory function of patients,” says author Dr. Yongwen Chen of Third Military Medical University in China, adding that “more urgent, early intervention may be required in patients with low T lymphocyte counts.”
Coffee has been linked to changes on our DNA that affect how active certain genes are. The finding may help explain some of coffee’s touted health benefits.
ROBOTS will raise one in three children in the future, an AI expert says.
Dr Michelle Tempest says the droids will feed, exercise and teach kids.
They will also change nappies and tell stories and artificial uteruses will develop foetuses.
Continue reading “Robots will feed, teach & exercise one in three kids by 2050, expert claims” »
